A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Name: A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
License: Public Domain

Pfizer

ClinicalTrials.gov · Datasets · License: Public Domain

meningitis, meningococcal

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 407777
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.